Abstract
Background
Obesity is an independent risk factor for diabetes, which is associated with significant morbidity and premature death. This study aims to evaluate the impact of laparoscopic adjustable gastric banding (LAGB) on a cohort of morbidly obese diabetics.
Methods
Inclusion and exclusion criteria were applied to consecutive diabetic patients undergoing LAGB. Demographic and disease-specific data were collected at baseline and 6-monthly intervals corresponding to follow-up assessments. Minimum follow-up was 24 months. Normally distributed variables were assessed with one-way analysis of variance/t tests; proportions were analysed with chi-squared/Fisher’s exact tests. Follow-up was ≥90 % complete at each time point.
Results
One hundred twenty patients with a median age of 43.3 years, mean (± standard deviation (SD)) pre-op body mass index (BMI) of 48.7 (±8) kg/m2, and HbA1c of 8.6 (±2) % were included. BMI reduced significantly, with annual post-operative means of 41.4 ± 7.8, 39.9 ± 7.7, 39.5 ± 7.8, 39.3 ± 7.1 and 36.6 ± 5.4 kg/m2 (p < 0.001). Corresponding percentage excess body weight lost was 32.8 ± 18, 39.8 ± 21.4, 38.5 ± 21.3, 37.0 ± 22.3 and 43.1 ± 14.1 %. HbA1c was significantly lower at each time point until 30 months post-operatively (p < 0.001). Thereafter, differences were insignificant, and HbA1c was comparable to pre-operative levels by 5 years. Seventy-six (63 %) patients achieved an HbA1c <7 % at 30 months (p < 0.001). Twenty-six (23 %) patients achieved remission from diabetes. The cumulative 5-year cost saving from reductions in anti-diabetes medications was £1650/patient. There were no mortalities, and 18 device explants.
Conclusions
Modest but durable weight loss associated with significant improvements in glycaemic control and anti-diabetic medication use have been demonstrated. Peak effects occur within 24–30 months and diminish thereafter, possibly reflecting progression of pathological processes due to residual obesity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62–9.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
American Diabetes Association. Executive summary: standards of medical care in diabetes—2010. Diabetes Care. 2010;33:S4–10.
UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
Sjostrom L, Lindroos A, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.
Singhal R, Kitchen M, Bridgwater S, et al. Metabolic outcomes of obese diabetic patients following laparoscopic adjustable gastric banding. Obes Surg. 2008;18:1400–4.
Parikh M, Ayoung-Chee P, Romanos E, et al. Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion. J Am Coll Surg. 2007;205:631–5.
Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol. 2009;8:37. doi:10.1186/1475-2840-8-37.
Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year. Obes Surg. 2005;15:641–7.
Deitel M. Update: why diabetes does not resolve in some patients after bariatric surgery. Obes Surg. 2011;21:794–6.
Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet (London). 2011;378:182–97.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203.
Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19:1646–56.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Conflict of Interest
The authors declare that they have no competing interests.
Informed Consent
Informed consent was obtained from all participants included in the study.
Rights and permissions
About this article
Cite this article
Egan, R.J., Johnson, A.B., Morgan, J.D.T. et al. The Impact of Laparoscopic Adjustable Gastric Banding on an NHS Cohort of Type 2 Diabetics: a Prospective Cohort Study. OBES SURG 26, 2006–2013 (2016). https://doi.org/10.1007/s11695-015-2039-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-015-2039-2